Adherencia a fesoterodina en mujeres con vejiga hiperactiva en la práctica clínica diaria / Adherence to fesoterodine in women with overactive bladder in routine clinical practice

Objetivos: Valorar a corto plazo la adherencia al tratamiento con fesoterodina e identificar las causas de la falta de adherencia o abandono en la práctica clínica diaria. El objetivo secundario fue estimar los resultados desde el punto de vista del paciente. Métodos: Este fue un estudio observacional, retrospectivo, y multicéntrico, llevado a cabo en una muestra poblacional de mujeres con vejiga hiperactiva (VH), en tratamiento con fesoterodina durante al menos 3 meses. La adherencia a la medicación se valoró mediante el test Morisky-Green. Los resultados desde el punto de vista del paciente fueron valorados empleando los cuestionarios cortos de incontinencia (ICIQ-SF) y vejiga hiperactiva (OAB-qSF) y la escala del beneficio del tratamiento (TBS). Resultados: Se incluyeron 120 mujeres con una edad media (desviación estándar [DE]) de 62,2 (12,0) años con VH grave según la puntuación media (DE) del ICIQ-SF (13,2 [4,0]). El 42,1% de las pacientes fueron consideradas cumplidoras con el tratamiento de fesoterodina. Las principales causas de incumplimiento/abandono indicadas por el 57,9% restantes fueron los efectos adversos (62,2%) y la falta de beneficio clínico (20,0%). Tanto el grado de enfermedad como las molestias debidas a los síntomas de la VH percibidas por los pacientes y el impacto en su calidad de vida mejoraron significativamente después de 3 meses del tratamiento con fesoterodina (p < 0,0001). La mayoría de los pacientes indicaron que sus problemas urinarios habían sufrido una gran mejora o habían mejorado. Conclusión: En la práctica clínica diaria un elevado porcentaje de pacientes fueron considerados cumplidores con el tratamiento de fesoterodina y percibieron los beneficios que dicho tratamiento proporcionaba después de 3 meses de iniciarlo. Sin embargo, más de la mitad de la población de estudio no cumplió o abandonó el tratamiento debido principalmente a intolerancia o falta de eficacia

Objectives: To assess the short-term compliance with fesoterodine treatment and to identify the reasons for lack of adherence and discontinuation in routine clinical practice. The secondary aim was to estimate the patient-reported outcomes. Methods: This was an observational retrospective, multicenter study conducted in a sample of women with overactive bladder on fesoterodine treatment for at least three months. Adherence to medication was assessed using the Morisky-Green test. Patient-reported outcomes were assessed using the Incontinence Questionnaire Short Form (ICIQ-SF), Overactive Bladder Questionnaire Short Form (OAB-qSF), and Treatment Benefit Scale (TBS). Results: One hundred and twenty women with a mean age [standard deviation (SD)] of 62.2 (12.0) years with severe OAB [mean (SD) ICIQ-SF score 13.2 (4.0)] were included. 42.1% of the patients were considered compliant with fesoterodine treatment. The main causes for non-compliance/discontinuation stated by the remaining 57.9% of the patients were adverse events (62.2%) and lack of clinical benefits (20.0%). The illness status as well as the patient-perceived bother occasioned by the OAB symptoms and their impact on the quality of life improved significantly after three months on fesoterodine treatment (p < 0.0001). Most of the patients stated that the current state of their urinary problems had greatly improved/ improved. Conclusion:In routine clinical practice, a high percentage of patients were adherent to fesoterodine and perceived the benefit that the treatment provided them three months after starting treatment. However, more than half of the study population failed to comply or discontinued the treatment mainly due to intolerance or lack of efficacy

Los cuestionarios en la evaluación de la actividad y función sexual en mujeres con incontinencia urinaria y prolapso de órganos pélvicos / Questionnaires in the assessment of sexual function in women with urinary incontinence and pelvic organ prolapse

Contexto: La integración del cuidado de la salud sexual en la práctica clínica es importante. En las mujeres con enfermedad del suelo pélvico se da más importancia a la evaluación de los defectos anatómicos, a la función urinaria y anorrectal que a la función sexual. Métodos: Se realizó una revisión y un análisis manual de las publicaciones relacionadas con la evaluación de la salud sexual en uroginecología, en Medline utilizando términos de búsqueda previamente definidos. Se incluyeron solo artículos publicados en inglés y en español. Resultados: Solo el 50% de las mujeres que consultan por un problema uroginecológico son sexualmente activas, de ellas el 60% refieren algún tipo de disfunción sexual. Los cuestionarios y las escalas de sexualidad facilitan la discusión entre la mujer y el profesional de la salud en los diversos aspectos de su vida sexual, su utilización rutinaria puede facilitar el diagnóstico de la disfunciones sexuales y un mejor control de los resultados de los tratamientos. El Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ) y el PISQ-IR (IUGA-revised) son los únicos cuestionarios de función sexual femenina validados que han sido desarrollados específicamente para evaluar la función sexual en mujeres con incontinencia urinaria y/o prolapso de órganos pélvicos. El PISQ-IR, además, permite evaluar el impacto en la función sexual en mujeres que no son sexualmente activas, así como en mujeres con incontinencia anal y está diseñado para su validación internacional. Conclusiones: La evaluación de la función sexual mediante cuestionarios específicos facilita la identificación de las disfunciones sexuales asociadas a la enfermedad del suelo pélvico. La inclusión de cuestionarios de sexualidad como medida de resultados permite analizar el impacto de los tratamientos aplicados en la vida sexual de las mujeres con problemas uroginecológicos

Context: Integrating sexual health in clinical practice is important. In women with pelvic floor disorders, the evaluation of the anatomical defects, lower urinary tract function and the anorectal function often receives more attention than the sexual function. Methods: Review of Medline using defined search terms to identify articles related to sexual health assessment in urogynecology and manual analyses was performed. Only articles published in English or Spanish were included. Results: Only 50% of women attending urogynecological clinics are sexually active. Of those, 60% present with some sort of sexual sexual dysfunction (FSD). Questionnaires and sexuality scales would facilitate discussion of sexual matters between the Health Care professionals and the women, and may increase the likelihood of FSD being diagnosed. The Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ) and the PISQ-IR (IUGA-Revised) are the only female sexual function specific questionnaires currently validated and developed specifically to assess sexual function in women with urinary incontinence and/or pelvic organ prolapse. Furthermore, the PISQ-IR also allows evaluation of the outcomes of women who are not sexually active when requiring urogynecologic care. PISQ-IR is also designed for international validation. In order to use the PISQ-IR in Spain, a proper interpretation and validation of the questionnaire is needed. Conclusions: The evaluation of sexual function through specific questionnaires facilitates the identification of the sexual dysfunctions associated to the pelvic floor disorders. The inclusion of sexuality questionnaires as an outcome measure allows to analyze the impact in the sexual life of women treated for an urogynecological problem

Questionnaires in the assessment of sexual function in women with urinary incontinence and pelvic organ prolapse.

CONTEXT: Integrating sexual health in clinical practice is important. In women with pelvic floor disorders, the evaluation of the anatomical defects, lower urinary tract function and the anorectal function often receives more attention than the sexual function. METHODS: Review of Medline using defined search terms to identify articles related to sexual health assessment in urogynecology and manual analyses was performed. Only articles published in English or Spanish were included. RESULTS: Only 50% of women attending urogynecological clinics are sexually active. Of those, 60% present with some sort of sexual sexual dysfunction (FSD). Questionnaires and sexuality scales would facilitate discussion of sexual matters between the Health Care professionals and the women, and may increase the likelihood of FSD being diagnosed. The Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ) and the PISQ-IR (IUGA-Revised) are the only female sexual function specific questionnaires currently validated and developed specifically to assess sexual function in women with urinary incontinence and/or pelvic organ prolapse. Furthermore, the PISQ-IR also allows evaluation of the outcomes of women who are not sexually active when requiring urogynecologic care. PISQ-IR is also designed for international validation. In order to use the PISQ-IR in Spain, a proper interpretation and validation of the questionnaire is needed. CONCLUSIONS: The evaluation of sexual function through specific questionnaires facilitates the identification of the sexual dysfunctions associated to the pelvic floor disorders. The inclusion of sexuality questionnaires as an outcome measure allows to analyze the impact in the sexual life of women treated for an urogynecological problem.

Adherence to fesoterodine in women with overactive bladder in routine clinical practice.

OBJECTIVES: To assess the short-term compliance with fesoterodine treatment and to identify the reasons for lack of adherence and discontinuation in routine clinical practice. The secondary aim was to estimate the patient-reported outcomes. METHODS: This was an observational retrospective, multicenter study conducted in a sample of women with overactive bladder on fesoterodine treatment for at least three months. Adherence to medication was assessed using the Morisky-Green test. Patient-reported outcomes were assessed using the Incontinence Questionnaire Short Form (ICIQ-SF), Overactive Bladder Questionnaire Short Form (OAB-qSF), and Treatment Benefit Scale (TBS). RESULTS: One hundred and twenty women with a mean age [standard deviation (SD)] of 62.2 (12.0) years with severe OAB [mean (SD) ICIQ-SF score 13.2 (4.0)] were included. 42.1% of the patients were considered compliant with fesoterodine treatment. The main causes for non-compliance/discontinuation stated by the remaining 57.9% of the patients were adverse events (62.2%) and lack of clinical benefits (20.0%). The illness status as well as the patient-perceived bother occasioned by the OAB symptoms and their impact on the quality of life improved significantly after three months on fesoterodine treatment (p<0.0001). Most of the patients stated that the current state of their urinary problems had greatly improved/ improved. CONCLUSION: In routine clinical practice, a high percentage of patients were adherent to fesoterodine and perceived the benefit that the treatment provided them three months after starting treatment. However, more than half of the study population failed to comply or discontinued the treatment mainly due to intolerance or lack of efficacy.